Newer therapeutic strategies for soft-tissue sarcomas

被引：8
作者：
Bourcier, Kevin [1 ,2 ]
Italiano, Antoine [1 ,2 ,3 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, 229 Cours Argonne, F-33000 Bordeaux, France
[2] Inst Bergonie, Sarcoma Unit, 229 Cours Argonne, F-33000 Bordeaux, France
[3] Univ Bordeaux, Bordeaux, France
来源：
PHARMACOLOGY & THERAPEUTICS | 2018年 / 188卷
关键词：
Sarcoma; Metastatic disease; Chemotherapy; Epigenetics; Targeted therapy; Immunotherapy; ERIBULIN MESYLATE; OPEN-LABEL; PHASE-II; DEDIFFERENTIATED LIPOSARCOMA; NUCLEOTIDE-EXCISION; UNIQUE MECHANISM; P53; PATHWAY; ECTEINASCIDIN-743; ET-743; EXPRESSION;
D O I：
10.1016/j.pharmthera.2018.02.014
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Metastatic soft-tissue sarcoma (STS), a devastating disease, has a median overall survival of only 12-18 months. Until recently, therapeutic options were limited and relied primarily on the use of anthracycline-based chemotherapy. Over the past two decades, improvement in the knowledge of the biology of STS has allowed the investigation of new therapeutic strategies including new cytotoxic agents, epigenetic drugs, specific targeted therapies, and immunotherapeutic treatments. (C) 2018 Published by Elsevier Inc.
引用
收藏
页码：118 / 123
页数：6
相关论文
共 66 条
[1]   A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas [J].
Bean, Gregory R. ;
Kremer, Jeff C. ;
Prudner, Bethany C. ;
Schenone, Aaron D. ;
Yao, Juo-Chin ;
Schultze, Matthew B. ;
Chen, David Y. ;
Tanas, Munir R. ;
Adkins, Douglas R. ;
Bomalaski, John ;
Rubin, Brian P. ;
Michel, Loren S. ;
Van Tine, Brian A. .
CELL DEATH & DISEASE, 2016, 7 :e2406-e2406
[2]   PDL1 expression is an independent prognostic factor in localized GIST [J].
Bertucci, Francois ;
Finetti, Pascal ;
Mamessier, Emilie ;
Pantaleo, Maria Abbondanza ;
Astolfi, Annalisa ;
Ostrowski, Jerzy ;
Birnbaum, Daniel .
ONCOIMMUNOLOGY, 2015, 4 (05)
[3]   The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma [J].
Bid, Hemant K. ;
Phelps, Doris A. ;
Xaio, Linlin ;
Guttridge, Denis C. ;
Lin, Jiayuh ;
London, Cheryl ;
Baker, Laurence H. ;
Mo, Xiaokui ;
Houghton, Peter J. .
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (05) :1018-1028
[4]  
Chawla S.P, 2013, J CLIN ONCOLOGY, P10514
[5]   Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas [J].
Chawla, Sant P. ;
Ganjoo, Kristen N. ;
Schuetze, Scott ;
Papai, Zsuzsanna ;
Van Tine, Brian Andrew ;
Choy, Edwin ;
Liebner, David A. ;
Agulnik, Mark ;
Chawla, Shanta ;
Wieland, Scott ;
Levitt, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[6]   First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma A Phase 2b Randomized Clinical Trial [J].
Chawla, Sant P. ;
Papai, Zsuzsanna ;
Mukhametshina, Guzel ;
Sankhala, Kamalesh ;
Vasylyev, Leonid ;
Fedenko, Alexander ;
Khamly, Kenneth ;
Ganjoo, Kristen ;
Nagarkar, Rajnish ;
Wieland, Scott ;
Levitt, Daniel J. .
JAMA ONCOLOGY, 2015, 1 (09) :1272-1280
[7]  
Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015
[8]   MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells [J].
Coll-Mulet, Llorenc ;
Iglesias-Serret, Daniel ;
Santidrian, Antonio F. ;
Cosialls, Ana M. ;
de Frias, Merce ;
Castano, Esther ;
Campas, Clara ;
Barragan, Montserrat ;
Fernandez de Sevilla, Alberto ;
Domingo, Alicia ;
Vassilev, Lyubomir T. ;
Pons, Gabriel ;
Gil, Joan .
BLOOD, 2006, 107 (10) :4109-4114
[9]  
Curiel T.J, 2013, CANC IMMUNOTHERAPY P
[10]   Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials [J].
D'Angelo, Sandra P. ;
Mahoney, Michelle R. ;
Van Tine, Brian A. ;
Atkins, James ;
Milhem, Mohammed M. ;
Jahagirdar, Balkrishna N. ;
Antonescu, Cristina R. ;
Horvath, Elise ;
Tap, William D. ;
Schwartz, Gary K. ;
Streicher, Howard .
LANCET ONCOLOGY, 2018, 19 (03) :416-426
1234567